Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing our results , evaluating both anatomical and functional outcomes of DEX therapy for refractory DME.
Our study aims at evaluating both anatomical and functional outcomes of DEX therapy for cases of refractory DME, with both a single injection, and /or with retreatments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravitreal Dexamethasone Implant for refractory Diabetic macular edema: | Drug | Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Central macular thickness (in microns) (CMT change ) | Change in Central macular thickness (in microns) (CMT change ) | between baseline and 6 months |
| Change in Best corrected visual acuity (BCVA change) ) | lines of Change in Best corrected visual acuity (BCVA change) ) | between baseline and 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of DEX injections | Number of DEX injections | between baseline and 6 months |
| Shift to anti-VEGF during follow-up | Shift to anti-VEGF during follow-up (Yes or No) |
Not provided
Inclusion Criteria:
• Age: 16 or older (Adults)
Exclusion Criteria:
• Phakic eyes
Not provided
Not provided
Retrospective Review of records of patients with Non-tractional diffuse diabetic macular edema (NTDME), for whom Ozurdex had been used , in the period between 2016 and 2022.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kasr alainy faculty of medicine | Cairo | 12311 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002123 | Calcium Dobesilate |
| ID | Term |
|---|---|
| D001557 | Benzenesulfonates |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
| between baseline and 6 months |
| Duration of follow-up ( months) | Duration of follow-up ( months) | between baseline and 6 months |
| CMT change > 100 u | CMT change > 100 u (yes / No) | between baseline and 6 months |
| CMT change > 200 u | CMT change > 200 u (yes / No) | between baseline and 6 months |
| BCVA change >= 2 lines | BCVA change >= 2 lines (yes / No) | between baseline and 6 months |
| Complications : ocular hypertension, pseudo uveitis, endophthalmitis, RD | Complications : ocular hypertension, pseudo uveitis, endophthalmitis, RD (yes / No) | between baseline and 6 months |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001190 | Arylsulfonates |
| D017739 | Arylsulfonic Acids |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |